Jennifer Amengual, MD
Medical Oncology · New York, NYNPI 1073718854
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $28,528 of the $33,980 with a category attached, or 84.0%. 17 manufacturers reported payments, led by Astrazeneca UK Limited at 50.9% of the total. Reporting peaked in 2023 at $9,466 and has fallen 84.1% since, to $1,507 in 2025.
Across 31 payments — averaging $1096.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$17K
- Daiichi Sankyo Inc.$7K
- Epizyme, Inc.$4K
- Incyte Corporation$2K
- ADC Therapeutics America, Inc.$1K
- Karyopharm Therapeutics Inc.$1K
- plus $2K from 11 others
Across 171 payments — averaging $17,732 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Biopharmaceuticals, Inc$1.1M
- Incyte Corporation$770K
- Epizyme, Inc.$599K
- Merck$146K
- Bristol Myers Squibb$132K
- Acrotech Biopharma Inc.$118K
- plus $186K from 2 others
What the payments were for
- Consulting fees$28,52884%
- Speaking & faculty fees$3,44910%
- Travel & lodging$1,0533%
- Food & beverage$9323%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 8 | $17,296 |
| Daiichi Sankyo Inc. | 3 | $6,580 |
| Epizyme, Inc. | 4 | $3,522 |
| Incyte Corporation | 1 | $2,153 |
| ADC Therapeutics America, Inc. | 1 | $1,400 |
| Karyopharm Therapeutics Inc. | 1 | $1,274 |
| Seagen Inc. | 3 | $1,192 |
| Secura Bio, Inc. | 1 | $168 |
| AstraZeneca | 1 | $135 |
| Pfizer | 1 | $82 |
| Genmab U.S., Inc. | 1 | $56 |
| Gilead | 1 | $26 |
| Adaptive Biotechnologies Corporation | 1 | $25 |
| Amgen | 1 | $19 |
| Merck | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Beigene USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,980 in reported general payments places this provider in the 70th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in New York
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
- Joshua BrodyNew York$492K
- Aiwu HeNew York$445K
- Raajit RampalNew York$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.